ECSP12012031A - Composición farmacéutica que comprende oligopéptidos - Google Patents

Composición farmacéutica que comprende oligopéptidos

Info

Publication number
ECSP12012031A
ECSP12012031A ECSP12012031A ECSP12012031A EC SP12012031 A ECSP12012031 A EC SP12012031A EC SP12012031 A ECSP12012031 A EC SP12012031A EC SP12012031 A ECSP12012031 A EC SP12012031A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical composition
oligopeptides
includes oligopeptides
lipophilic
amphiphilic
Prior art date
Application number
Other languages
English (en)
Inventor
Marcus Eber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44145957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012031(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP12012031A publication Critical patent/ECSP12012031A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de oligopéptidos, con preferencia oligopéptidos cíclicos, en donde dicha composición también comprende uno o varios compuestos lipofílicos y/o anfifílicos, en presencia o ausencia de agua como los ingredientes principales, al uso de los compuestos lipofílicos y/o anfifílicos para preparar composiciones farmacéuticas de dichos oligopéptidos y a métodos de preparación de tal composición farmacéutica.
ECSP12012031 2009-12-10 2012-07-09 Composición farmacéutica que comprende oligopéptidos ECSP12012031A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28531309P 2009-12-10 2009-12-10
US41662810P 2010-11-23 2010-11-23

Publications (1)

Publication Number Publication Date
ECSP12012031A true ECSP12012031A (es) 2012-08-31

Family

ID=44145957

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012031 ECSP12012031A (es) 2009-12-10 2012-07-09 Composición farmacéutica que comprende oligopéptidos

Country Status (20)

Country Link
US (1) US9433577B2 (es)
EP (1) EP2509583B1 (es)
JP (1) JP5946770B2 (es)
KR (1) KR20120104316A (es)
CN (1) CN102652015B (es)
AU (1) AU2010330364B2 (es)
BR (1) BR112012012862A2 (es)
CA (1) CA2783732A1 (es)
CL (1) CL2012001310A1 (es)
EA (1) EA022700B1 (es)
EC (1) ECSP12012031A (es)
ES (1) ES2742263T3 (es)
IL (1) IL220097A (es)
MX (1) MX2012006450A (es)
NZ (1) NZ601109A (es)
PE (1) PE20121359A1 (es)
PH (1) PH12012500754A1 (es)
SG (1) SG181487A1 (es)
WO (1) WO2011069629A2 (es)
ZA (1) ZA201205103B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1012789A2 (pt) 2009-05-20 2018-01-16 Merck Patent Gmbh "materiais sólidos de {ácido[(2s,5r,8s,11s)-5-benzil-11 -(3-guanidino-propil)-8-isopropil-7-metil-3,6,9,12,15- pentaoxo-1,4,7,10,13-penta-aza-ciclopentadec-2-il]- acético} e métodos para obter os mesmos"
KR102095670B1 (ko) 2010-05-14 2020-03-31 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
AU2012266803B2 (en) 2011-06-09 2017-02-02 Merck Patent Gmbh Treatment of cancers and metastases with suspensions of cilengitide in carrier
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP7457642B2 (ja) 2017-04-03 2024-03-28 ビオンテック ユーエス インコーポレイテッド タンパク質抗原およびその使用
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
WO2019246286A1 (en) 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018147A1 (en) * 1991-04-19 1992-10-29 Affinity Biotech, Inc. Convertible microemulsion formulations
NZ243721A (en) * 1991-07-26 1994-11-25 Smithkline Beecham Corp Self-emulsifying microemulsion comprising water soluble drug, high hlb surfactant and a lipophilic phase containing fatty acid triglyceride and a low hlb surfactant
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
CZ299790B6 (cs) * 1996-08-22 2008-11-26 Skyepharma Canada Inc. Kompozice mikrocástic ve vode nerozpustné látky, farmaceutická kompozice, zpusob prípravy stabilních cástic, mikrocástice ve vode nerozpustné nebo slabe rozpustné slouceniny, kompozice obsahující tyto mikrocástice a zpusob prípravy mikrocástic
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
UA71608C2 (en) 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
EP2116228A1 (en) * 2001-10-19 2009-11-11 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
CN1791386A (zh) 2003-05-19 2006-06-21 巴克斯特国际公司 抗癫痫和抗痴呆药物以及免疫抑制剂的小－颗粒药物制剂
ATE411006T1 (de) * 2004-06-03 2008-10-15 Bracco Research Sa Liposomale anordnung für die therapeutische und/oder diagnostische anwendung
WO2009043441A1 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag D-ala-gln-octadecyl ester as a therapeutic agent
CN101990425B (zh) * 2008-04-08 2016-01-20 默克专利股份有限公司 包含环肽的组合物和使用方法
BRPI1012789A2 (pt) * 2009-05-20 2018-01-16 Merck Patent Gmbh "materiais sólidos de {ácido[(2s,5r,8s,11s)-5-benzil-11 -(3-guanidino-propil)-8-isopropil-7-metil-3,6,9,12,15- pentaoxo-1,4,7,10,13-penta-aza-ciclopentadec-2-il]- acético} e métodos para obter os mesmos"

Also Published As

Publication number Publication date
BR112012012862A2 (pt) 2016-08-16
AU2010330364A1 (en) 2012-07-26
NZ601109A (en) 2014-06-27
EP2509583B1 (en) 2019-05-15
ES2742263T3 (es) 2020-02-13
KR20120104316A (ko) 2012-09-20
ZA201205103B (en) 2013-03-27
MX2012006450A (es) 2012-06-28
US9433577B2 (en) 2016-09-06
WO2011069629A3 (en) 2012-03-15
CA2783732A1 (en) 2011-06-16
JP2013513556A (ja) 2013-04-22
IL220097A (en) 2017-03-30
WO2011069629A2 (en) 2011-06-16
PE20121359A1 (es) 2012-10-15
JP5946770B2 (ja) 2016-07-06
CL2012001310A1 (es) 2012-10-12
CN102652015A (zh) 2012-08-29
CN102652015B (zh) 2016-08-03
EP2509583A2 (en) 2012-10-17
AU2010330364B2 (en) 2016-05-19
EA201200850A1 (ru) 2013-01-30
PH12012500754A1 (en) 2018-03-21
EA022700B1 (ru) 2016-02-29
SG181487A1 (en) 2012-07-30
US20120288539A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
EA201200850A1 (ru) Фармацевтическая композиция, содержащая олигопептиды
GT201400136A (es) Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos
ECSP12011939A (es) Compuestos Lipopéptidos y métodos relacionados
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
ECSP12011935A (es) Triazolopiridinas
MX2013003365A (es) Composicion farmaceutica.
GT201200334A (es) Morfolinopirimidinas y su uso en terapia
CO6650348A2 (es) Triazolopiridinas sustituidas
DOP2014000133A (es) Triazolopiridinas sustituidas
MX2013012289A (es) Triazolopiridinas.
CL2012000508A1 (es) Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas.
MX2012008717A (es) Composiciones para el cuidado oral.
CO6640301A2 (es) Compuestos ologo-benzamida y su uso
BR112013019924A8 (pt) Composições para cuidado oral
CL2013001945A1 (es) Compuestos derivados de pirazol de fórmulas (ia) o (ib), antagonistas de crth2; composiciones farmaceuticas que los contienen; combinaciones farmaceuticas; su uso en la prevencion y/o el tratamiento de trastornos inflamatorios, infecciosos e inmunorreguladores.
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
MX375183B (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
CR11755A (es) Dronedarona para la prevencion de la cardioversion
AR075228A1 (es) Composiciones para el tratamiento del cabello.
NZ610950A (en) Pharmaceutical compositions comprising alisporivir
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
MX2012007172A (es) Piperazinas como agentes antimalaria.
CO6501127A2 (es) Composiciones farmacéuticas que comprende oligopeptidos